Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Revenue (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Revenue for 9 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Revenue fell 51.0% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.5 million through Dec 2025, down 52.21% year-over-year, with the annual reading at $3.5 million for FY2025, 46.19% down from the prior year.
  • Revenue for Q4 2025 was $1.1 million at Marker Therapeutics, down from $1.2 million in the prior quarter.
  • The five-year high for Revenue was $2.5 million in Q1 2023, with the low at -$503005.0 in Q2 2023.
  • Average Revenue over 4 years is $1.1 million, with a median of $1.0 million recorded in 2022.
  • The sharpest move saw Revenue crashed 163.63% in 2023, then skyrocketed 647.66% in 2024.
  • Over 4 years, Revenue stood at $759143.0 in 2022, then skyrocketed by 39.17% to $1.1 million in 2023, then surged by 113.13% to $2.3 million in 2024, then crashed by 51.0% to $1.1 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $1.1 million, $1.2 million, and $861184.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.